A Normal Coronary Angiogram Is Not the Same as No Heart Disease. Here Is What Catheterization Actually Shows.

The Scene

The following scene is drawn from the composite of patients I have cared for in clinic and on the hospital floor. All identifying details are changed.

The ceiling tiles in the pre-procedure area of a major cardiac center are the same acoustic white as every other ceiling in every other hospital waiting room Patricia has ever sat in. She is 61 years old, a high school principal from the northwest suburbs of Chicago, and she is wearing a paper gown that does not close properly in the back. It is 6:40 in the morning.

The nurse cycling Patricia’s blood pressure cuff has explained the procedure four times. Patricia has a legal pad with questions. She knows the words “coronary angiogram” now. She can say them. She does not yet know what they mean in any concrete sense. What she knows is that three weeks ago, during a treadmill stress test at her internist’s office, her ECG showed something her cardiologist described as “changes I don’t want to dismiss.” She knows the phrase “possible blockage.” She knows she should not eat anything after midnight, which she did not.

What she does not know: what they are about to thread into her body, where it will travel, what it will show, what they will do if they find something, or how bad “something” can be.

This article is for Patricia. And for the roughly 1.5 million Americans who undergo diagnostic cardiac catheterization every year, most of whom sit in a pre-procedure bay at some point before the case feeling exactly as she does.

Cardiac catheterization is a diagnostic procedure in which a physician guides a thin plastic tube through the arterial system to the coronary arteries and takes pictures of them using contrast dye and X-ray. It is the gold standard for identifying obstructive coronary artery disease. It takes 30 to 60 minutes. It requires mild sedation but not general anesthesia. Most patients go home the same day.

That is what Patricia needs to know before the sedation takes hold. The rest of this article explains the rest.

What It Is

Cardiac catheterization refers to the passage of a catheter into the chambers of the heart or the coronary arteries for diagnostic or therapeutic purposes. In its most common form, the “diagnostic cath” or coronary angiogram, it visualizes the coronary arteries to determine whether they are narrowed or blocked.

The term encompasses several distinct but related procedures:

Coronary angiography is the injection of iodinated contrast dye into the coronary ostia (the openings of the coronary arteries at the aortic root) under fluoroscopic guidance, producing real-time X-ray images of the arterial lumen. Obstructions show as areas of contrast dropout or narrowing.

Left ventriculography uses a pigtail catheter positioned in the left ventricle with contrast injection to assess global and regional left ventricular function, mitral regurgitation severity, and wall motion abnormalities.

Right heart catheterization (Swan-Ganz catheterization) uses a balloon-tipped catheter advanced through the venous system into the right heart and pulmonary artery to measure filling pressures, cardiac output, and vascular resistance. This is less commonly combined with diagnostic coronary angiography and is a separate procedure with distinct indications.

Cardiac catheterization is not a surgery. No incision is made. The entry point is an arterial puncture, typically at the wrist (radial artery) or the groin (femoral artery), through which a sheath no larger than a ballpoint pen casing is placed. All hardware travels through this single entry point.

The Scale of the Procedure

More than 1.5 million diagnostic cardiac catheterizations are performed annually in the United States 5 / Solid . The procedure is the most frequently performed invasive cardiovascular diagnostic test. Its use has risen with an aging population and the expansion of indications, and its safety has improved substantially over four decades of technique refinement.

Roughly one-third of diagnostic catheterizations in stable patients are performed in women. Women undergo diagnostic cath at a later age than men on average (mid-sixties vs. late fifties), are more likely to have non-obstructive coronary anatomy when catheterized, and are more likely to have microvascular disease not visible on standard angiography 5 / Solid .

When Catheterization Is Appropriate

The ACC/AHA guidelines classify coronary angiography as a Class I indication (benefit substantially outweighs risk) in:

• Acute coronary syndromes (STEMI, NSTEMI, unstable angina) where timely coronary evaluation changes management
• Stable ischemic heart disease with high-risk features on non-invasive testing (>10% ischemic territory on nuclear imaging, EF below 35% with symptoms, positive stress test at low workload)
• New-onset heart failure of uncertain etiology where CAD must be excluded before non-ischemic etiologies are assumed
• Pre-operative evaluation for high-risk cardiac surgery in patients with known or suspected coronary disease

Not every patient with chest pain needs a cardiac catheterization. The PROMISE trial randomized 10,003 patients with stable chest pain to either coronary CTA (which provides non-invasive anatomical information) or standard functional testing. The coronary CTA arm had a diagnostic catheterization rate of 12.2% versus 8.1% in the functional testing arm, while maintaining equivalent rates of major adverse cardiac events at 25 months 5 / Solid . For many patients with stable symptoms and low-to-intermediate pretest probability, non-invasive testing is the more appropriate first step.

The decision to proceed directly to catheterization requires clinical judgment about symptom burden, risk profile, and the patient’s ability to complete non-invasive testing. When a patient presents with rest angina, a rising troponin, or hemodynamic instability, catheterization proceeds without the intermediate step.

The Mechanism

Understanding what catheterization actually does requires understanding what the coronary arteries look like, what can go wrong with them, and what the procedure reveals.

Coronary Anatomy

The heart is a pump that requires its own blood supply. The left main coronary artery arises from the aortic root just above the left coronary cusp, divides within centimeters into the left anterior descending (LAD) and left circumflex (LCX) arteries. The right coronary artery (RCA) arises separately from the right coronary cusp. These three vessels and their branches supply the entire myocardium. In 85% of the population, the RCA is dominant, supplying the posterior descending artery (PDA) and the posterior-lateral branches. In 8%, the LCX is dominant. In 7%, there is co-dominance 5 / Solid .

What Atherosclerosis Does to Coronary Arteries

Plaque accumulates within the arterial wall over decades through the oxidation of LDL particles, macrophage infiltration, foam cell formation, and fibrous cap development. Early plaques produce no luminal narrowing because the artery initially remodels outward (the Glagov phenomenon) 5 / Solid . Only when the plaque occupies more than 40% of the vessel cross-section does the lumen begin to narrow. Angiography cannot detect this early outward remodeling. It shows only lumen; it shows nothing about plaque burden outside the lumen. This is a fundamental limitation the reader should understand.

A lesion producing a 70% reduction in lumen diameter reduces the cross-sectional area by 91%. At this threshold, the reduction in blood flow becomes flow-limiting under exercise stress conditions, and the patient experiences angina or ischemia. A 50% stenosis may not be flow-limiting at rest but can become so with exertion. A lesion below 50% is typically not flow-limiting at any workload.

What Contrast and Fluoroscopy Show

The catheter delivers iodinated contrast, which is radiopaque: it absorbs X-rays and appears white on fluoroscopy. The coronary lumen fills with contrast and the outline of the lumen becomes visible. Narrowings appear as focal areas where the column of contrast pinches. Total occlusions appear as abrupt cutoffs. Irregularity of the lumen wall suggests non-obstructive plaque. Collateral vessels feeding territory beyond an occlusion may be visible.

The cardiologist interprets the angiogram in multiple projections to avoid foreshortening and overlap. Standard cath lab protocol images the left coronary in at least five projections (LAO cranial, LAO caudal, RAO cranial, RAO caudal, AP cranial) and the right coronary in two to three projections 5 / Solid 00500-3).

What Catheterization Cannot See

Angiography reveals lumen anatomy. It does not reveal plaque composition (fibrous cap thickness, lipid core size, plaque vulnerability). It does not reveal microvascular function. It does not reveal myocardial viability. It does not detect early non-obstructive plaque. Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) address the plaque composition gap; fractional flow reserve (FFR) addresses the physiological significance gap. Cardiac MRI addresses myocardial viability. These supplemental tools are covered in their own Foundations articles.

The Radial vs. Femoral Access Debate

For decades, femoral access (Judkins technique, described by Melvin Judkins in 1967) was the default approach. The femoral artery is large and accessible; the catheter course from groin to aortic root is short and direct. Hemostasis requires either manual compression for 15 to 20 minutes or a vascular closure device. Patients stay flat for two to six hours after femoral cases.

Radial access (Campeau transradial approach, described 1989; refined by Kiemeneij and colleagues in the 1990s) has progressively displaced femoral access as the primary approach in most high-volume centers worldwide. The MATRIX trial enrolled 8,404 patients with ACS randomized to radial versus femoral access. Radial access was associated with a lower rate of major adverse cardiovascular and cerebrovascular events (MACCE) at 30 days (8.8% vs. 10.3%; RR 0.85, 95% CI 0.74 to 0.99) and a significant reduction in the primary net adverse clinical event composite (10.4% vs. 12.4%; RR 0.83, 95% CI 0.73 to 0.96) 5 / Solid . Bleeding complications, the dominant driver of the outcome difference, were substantially lower with radial access.

Radial access requires assessment of the dual hand circulation via Allen test or Barbeau test before access is obtained. Radial artery spasm occurs in 5 to 10% of cases and can be managed with intra-arterial vasodilators (nitroglycerine, verapamil). The learning curve for radial access is longer than for femoral; operators performing fewer than 50 cases per year have higher cross-over rates to femoral 4 / Promising .

In the United States, radial access now accounts for approximately 65 to 70% of diagnostic catheterizations at high-volume centers 4 / Promising .

How It Is Used

The Pre-Procedure Workup

The workup before elective cardiac catheterization includes:

• Kidney function assessment. Iodinated contrast is nephrotoxic. Serum creatinine and estimated GFR are obtained. Patients with eGFR below 30 mL/min/1.73m2 require pre-procedure planning for contrast volume minimization, iso-osmolar contrast agents, and post-procedure monitoring. The PRESERVE trial (3,571 patients with CKD undergoing coronary angiography) found that sodium bicarbonate infusion did not reduce contrast-associated AKI compared to normal saline, and N-acetylcysteine provided no benefit 5 / Solid . Current practice emphasizes IV hydration and minimizing contrast volume, not pharmacological prevention.

• Anticoagulation management. Warfarin is typically held for 3 to 5 days before elective procedures; direct oral anticoagulants are held for 24 to 48 hours depending on renal function and the specific agent.

• Metformin. Held 48 hours before the procedure in patients with eGFR below 60 mL/min/1.73m2, due to lactic acidosis risk if contrast-induced AKI occurs (though this risk is very low with modern iso-osmolar contrast).

• Allergy pre-medication. Patients with prior contrast allergy receive a standard corticosteroid and antihistamine protocol. Severe anaphylaxis to contrast occurs in fewer than 1 in 10,000 procedures.

• Fasting. Four to six hours for solid food; clear liquids permitted up to two hours before.

The Procedure Itself

The patient lies supine on the fluoroscopy table. The access site (usually right wrist) is cleaned and draped. Local anesthesia (lidocaine) is injected at the puncture site. A small needle punctures the radial artery; a guidewire is advanced; the sheath is placed over the wire. The sheath is typically 5F or 6F (1.67 mm or 2 mm outer diameter).

Diagnostic catheters are pre-shaped to engage each coronary ostium. The Judkins Left 4 (JL4) catheter is the standard shape for the left coronary; the Judkins Right 4 (JR4) for the right. Radial access requires a modified set of catheter shapes (Ikari Left or radial-specific guides) because the path from wrist to aortic root creates different forces on the catheter. The catheters are flushed continuously with heparinized saline to prevent thrombus formation.

Contrast is injected by hand (small boluses of 4 to 8 mL) or by an automated injector while the fluoroscope records the images. The cardiologist reviews each run in real time, noting the presence, location, and severity of any stenosis.

Intravenous heparin is given when PCI follows the diagnostic study. For diagnostic-only cases, anticoagulation is institution-dependent.

Total fluoroscopy time for a routine diagnostic case is 3 to 8 minutes. Total procedure time is 20 to 45 minutes for an uncomplicated diagnostic case.

Radiation Exposure

Cardiac catheterization delivers ionizing radiation. The effective dose for a standard diagnostic coronary angiogram is approximately 7 mSv, comparable to 350 chest X-rays or about 2.5 years of background radiation 5 / Solid . This dose is meaningful but not prohibitive in the context of the diagnostic value. Patients who undergo multiple catheterizations over time accumulate dose; radiation dose tracking programs are standard in busy cardiac catheterization laboratories.

Interpreting the Results

The cardiologist quantifies stenosis severity visually (visual estimation) or with quantitative coronary analysis (QCA) software. Visual estimation is operator-dependent and has significant inter-observer variability for lesions in the 50 to 70% range 4 / Promising .

Stenosis terminology:

• Non-obstructive CAD: 1 to 49% stenosis in any vessel
• Moderate stenosis: 50 to 69% stenosis
• Significant stenosis: 70% or greater in a major epicardial vessel; 50% or greater in the left main

Functionally significant stenosis is not the same as anatomically significant stenosis. A 70% stenosis in a small vessel supplying a small territory may have less hemodynamic impact than a 60% stenosis in the proximal LAD. Physiological assessment with FFR (fractional flow reserve) or iFR (instantaneous wave-free ratio) is recommended by ACC/AHA guidelines for lesions in the intermediate range (40 to 70%) before proceeding to PCI 5 / Solid .

Geographic Access

In central Illinois, diagnostic cardiac catheterization is performed at Carle Foundation Hospital in Urbana-Champaign. More complex structural interventions (TAVR, MitraClip, Watchman) are concentrated at tertiary centers: Northwestern Medicine Bluhm Cardiovascular Institute in Chicago, OSF Saint Francis Medical Center in Peoria, and Memorial Medical Center in Springfield. Patients in rural central Illinois typically drive 45 to 90 minutes for cath lab access. For time-sensitive ACS presentations, Carle’s catheterization laboratory maintains 24/7 availability for primary PCI.

The Evidence

The Foundation: Coronary Angiography as Reference Standard

Coronary angiography has been the reference standard for the diagnosis of obstructive CAD for more than five decades. Its diagnostic performance benchmarks all other coronary imaging modalities. For detection of any angiographically significant stenosis (50% or greater), the sensitivity of the procedure itself is definitionally 100% by reference standard design. The relevant evidence question is whether the pre-procedure probability, the clinical indication, and the result change management in a way that improves patient outcomes.

PROMISE Trial: CTA vs. Functional Testing in Stable Chest Pain

PROMISE (Douglas PS, et al. N Engl J Med. 2015; doi:10.1056/NEJMoa1415516) enrolled 10,003 patients with stable chest pain and randomized them to coronary CTA (anatomical) versus standard functional testing (exercise ECG, nuclear imaging, or stress echo). The primary endpoint was the composite of death, MI, hospitalization for unstable angina, or major procedural complication. There was no significant difference in primary events (3.3% for CTA vs. 3.0% for functional testing; adjusted HR 1.04, 95% CI 0.83 to 1.29) 5 / Solid . CTA did identify more obstructive CAD (11.2% vs. 7.2% in the functional testing arm) and led to more subsequent catheterizations and coronary revascularizations. The trial established that CTA is an appropriate first-line test for stable symptoms, not that catheterization is unnecessary. What it did not show: the trial enrolled relatively low-risk patients (mean 10-year cardiovascular risk approximately 10%); results may not apply to higher-risk populations.

ISCHEMIA Trial: When Does Catheterization Change Outcomes?

The ISCHEMIA trial (Maron DJ, et al. N Engl J Med. 2020; doi:10.1056/NEJMoa1915922) enrolled 5,179 patients with stable ischemic heart disease and moderate-to-severe ischemia on non-invasive testing. Patients were randomized to an invasive strategy (coronary angiography followed by revascularization if feasible) versus an initial conservative strategy (medical therapy, with revascularization reserved for escalating symptoms or an ACS event). After a median follow-up of 3.2 years, the primary composite endpoint (CV death, MI, hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest) occurred in 13.3% of the invasive group and 15.5% of the conservative group (HR 0.93, 95% CI 0.80 to 1.08; not significant) 5 / Solid . The invasive strategy did not improve outcomes over medical therapy in stable patients with moderate-to-severe ischemia.

This finding reshaped practice for stable ischemic heart disease. What ISCHEMIA did not show: patients with unprotected left main disease, EF below 35%, or recent ACS were excluded. The trial did show an initial excess of procedural MIs in the invasive group followed by late protection against spontaneous MI. The 7-year follow-up data suggested late convergence favoring the invasive strategy for the subset of patients with multivessel CAD and diabetes 4 / Promising .

MATRIX Trial: Radial vs. Femoral Access

MATRIX (Valgimigli M, et al. N Engl J Med. 2015; doi:10.1056/NEJMoa1501049) enrolled 8,404 patients with ACS randomized to radial versus femoral access for coronary angiography and PCI. The primary endpoint of MACCE at 30 days favored radial access (8.8% vs. 10.3%; RR 0.85, 95% CI 0.74 to 0.99) 5 / Solid . Bleeding was the dominant mechanism: Bleeding Academic Research Consortium type 3 or 5 events occurred in 1.6% of radial versus 2.3% of femoral patients (RR 0.67, 95% CI 0.49 to 0.92). What it did not show: the survival benefit was driven by patients undergoing PCI for STEMI; for diagnostic-only cases, the mortality difference was not significant.

PRESERVE Trial: Contrast Nephropathy Prevention

PRESERVE (Weisbord SD, et al. N Engl J Med. 2018; doi:10.1056/NEJMoa1710933) enrolled 3,571 patients with CKD (eGFR 15 to 60 mL/min/1.73m2) undergoing coronary angiography in a 2x2 factorial design: sodium bicarbonate vs. isotonic saline; N-acetylcysteine vs. placebo. The primary outcome was contrast-associated acute kidney injury, dialysis, or death at 90 days. Neither sodium bicarbonate (OR 1.02; 95% CI 0.78 to 1.33) nor N-acetylcysteine (OR 0.99; 95% CI 0.76 to 1.29) reduced the primary outcome 5 / Solid . The trial definitively ended two decades of practice variation around renoprotective protocols. Current standard is IV isotonic saline alone with volume minimization.

Contrast Volume and Kidney Risk

The ratio of contrast volume to creatinine clearance (CV/CrCl) predicts AKI risk better than absolute contrast volume alone. A CV/CrCl ratio above 3.7 is independently associated with contrast-induced nephropathy 4 / Promising . Limiting contrast to less than 100 mL in patients with CKD stage 3 or greater is standard practice in most cath labs. Newer iso-osmolar contrast agents (iodixanol, ioversol) have equivalent nephrotoxic profiles to low-osmolar agents in most patients.

Complications: What the Data Show

Major complications from elective diagnostic catheterization are rare but not zero. In a systematic review of more than 300,000 procedures:

• Death: 0.11%
• Myocardial infarction: 0.05%
• Stroke: 0.07%
• Major vascular complication (requiring surgery or transfusion): 0.43%
• Contrast nephropathy requiring dialysis: 0.08%

These complication rates are higher in urgent versus elective settings, in patients with peripheral vascular disease, advanced CKD, and in those undergoing complex combined diagnostic-interventional cases. Radial access reduces vascular access site complications by approximately 60 to 70% compared with femoral access in meta-analyses 5 / Solid .

The Patient Experience

Patricia comes back from the procedure to a recovery bay. She has a TR Band (radial compression device) on her right wrist. It is transparent so the nurse can watch for hematoma. The nurse deflates it incrementally over two hours.

What she describes afterward is not pain. It is disorientation. “I could feel something moving inside me, but it didn’t hurt. There was a hot flush when they injected the dye. I asked if that was normal and the nurse said yes. Then it was over.”

This is the universal description. The contrast flush is mediated by contrast entering warm blood; it produces a diffuse warmth or heat sensation in the chest and sometimes the pelvis for 20 to 30 seconds. It is not dangerous. It is not the sensation of dye entering the coronary arteries, which patients cannot feel because coronary endothelium does not have temperature receptors in the relevant distribution.

What patients can feel: premature beats during catheter manipulation of the coronary ostia. The tip of the catheter briefly obstructs flow; the resulting ischemia causes a transient abnormal beat. It is arresting the first time. It passes within seconds of the catheter being withdrawn.

What Your Cardiologist Will Not Have Time to Explain

• The access site requires attention for 24 hours. Radial sites can develop a small hematoma if the compression band is removed too early. Femoral sites can develop a larger hematoma or, rarely, a pseudoaneurysm. Any significant swelling, bruising extending beyond the initial site, or a pulsatile mass at the access point requires same-day evaluation.

• The results are reviewed by your cardiologist, not by the proceduralist. In many centers, the interventional cardiologist performs the diagnostic case and then returns to speak with you in recovery. That conversation is brief and often occurs when the patient is still sedated and not retaining information well. Request a follow-up conversation within 48 hours while you are alert.

• “Non-obstructive CAD” is not the same as “your heart is fine.” Approximately 25 to 40% of patients undergoing catheterization for stable symptoms have non-obstructive disease (plaques present but less than 50% stenosis). This finding carries cardiovascular risk. It does not require stenting. It does require aggressive risk factor management. The PROMISE and ISCHEMIA data showed that non-obstructive CAD carries meaningful long-term risk and warrants statin and antiplatelet therapy in most patients 5 / Solid .

• Contrast can affect kidney function transiently. Most patients with normal kidney function see a mild, transient creatinine rise that resolves within 72 hours. Patients with CKD should have their creatinine rechecked 48 to 72 hours post-procedure.

• If the angiogram showed obstructive disease and you went on to have a stent placed the same day, the “diagnostic cath” and the “PCI” are reported as two procedures. You will receive two procedure codes on your explanation of benefits. This is appropriate and common. The decision to proceed to PCI at the same sitting depends on the anatomy, the operator’s assessment, and the availability of blood pressure support if needed.

Sex Differences in Catheterization

Women who undergo cardiac catheterization have different outcomes from men at the access site. Radial artery spasm rates are higher in women, attributed to smaller vessel diameter and different vasomotor tone 4 / Promising . Women have higher rates of vascular access complications with femoral access, including pseudoaneurysm and arteriovenous fistula, attributable to differences in femoral anatomy and body habitus 5 / Solid . The SAFE-PCI for Women trial showed that in women with ACS, radial access reduced major bleeding events relative to femoral access 5 / Solid .

Women are more likely than men to have non-obstructive coronary anatomy on diagnostic catheterization and more likely to have ischemia from microvascular dysfunction. The WISE study (Women’s Ischemia Syndrome Evaluation) demonstrated that approximately 50% of women with signs and symptoms of ischemia referred for catheterization had no obstructive coronary disease but had objective evidence of coronary microvascular dysfunction on functional testing 5 / Solid . Non-obstructive angiography in a woman with persistent symptoms is not reassurance. It is a prompt to evaluate microvascular function.

Decisions and Trade-Offs

When to Proceed vs. When to Pursue Non-Invasive Testing First

The decision between immediate catheterization and non-invasive testing is risk-stratified. Patients with ACS (rising troponin, rest pain, hemodynamic instability) proceed to catheterization without an intermediate non-invasive test. Patients with stable symptoms and low-to-intermediate pretest probability generally benefit from CTA or functional testing first. Patients with high pretest probability (prior MI, prior stent, three-vessel disease by prior imaging), moderate-to-severe ischemia on non-invasive testing, or symptoms inadequately managed with medical therapy are appropriately referred directly.

The 2021 ACC/AHA Chest Pain Guidelines formalized this approach, creating a risk-stratified pathway that uses coronary CTA as the preferred first-line test for most stable patients presenting with chest pain 5 / Solid .

The Benefit-Risk Framework

The relevant risk calculation is not “is this procedure dangerous?” but “does the information obtained change management in a way that reduces morbidity or mortality?”

For the patient with an ACS, the answer is definitively yes. For the patient with stable symptoms and moderate pretest probability who has not been adequately evaluated non-invasively, the answer is uncertain. For the patient with known severe three-vessel disease being considered for CABG, the answer is yes. For the patient with known non-obstructive CAD who wants reassurance, the ISCHEMIA data show that repeat invasive assessment changes outcomes only in very specific circumstances.

Cost and Access

In the United States, diagnostic cardiac catheterization is covered by Medicare and most commercial insurance for documented appropriate indications. The facility fee and professional fee combined typically range from $4,000 to $15,000 depending on complexity and geographic region, with patient responsibility after coverage varying widely by plan design. Patients without insurance face the full charge. In rural central Illinois, the nearest high-volume catheterization laboratory is at Carle Foundation Hospital (Urbana-Champaign); patients in more rural counties may require transfer to access the procedure within an appropriate timeframe for ACS presentations.

The Three Questions Every Patient Should Ask

1. “Why do I need a catheterization rather than a CTA or stress test first?” Any cardiologist recommending direct catheterization for stable symptoms should be able to answer this with specific reference to your risk score, your functional testing results, or your symptom burden. Vague answers like “it’s the gold standard” are insufficient.

2. “If you find a significant lesion, will you treat it at the same sitting or bring me back?” This matters for consent and for planning. Same-sitting PCI requires a different consent, different anticoagulation, and your partner knowing the potential scope of the procedure.

3. “What are the three complications you see most often in patients like me, and how would you manage each?” The honest answer is: access site hematoma (most common, managed with pressure and monitoring), contrast nephropathy (risk depends on baseline kidney function, managed with hydration and observation), and, rarely, dissection of the coronary ostium (managed immediately with PCI).

Clinical Synthesis

Cardiac catheterization sits at the intersection of diagnosis and intervention. Most patients who undergo it are past the window of primary prevention. The question they face is not whether they have coronary disease, but how much, where, and what to do about it. What preventive cardiology does for patients like Patricia is put that question in context before the sedation starts.

The clinical thesis here is built on early detection: knowing your ApoB, your CAC score, your VO2max before the stress test comes back positive. The patient who arrives at the catheterization lab without ever having had a coronary CTA, a CAC score, or a formal lipid analysis is a patient who arrived at the wrong place in the timeline. That is not a failure of character. It is a failure of the system to create a legible pathway from risk factor identification to appropriate testing.

If you have just been told you need a cardiac catheterization: The Signal Check is the right starting point. It gives your cardiologist’s recommendations context: what is your baseline lipid profile, what is your CAC score if it has not been obtained, what medications are indicated, and what comes after the procedure in terms of surveillance and secondary prevention.

If you have already had a catheterization and are working through the results: a structured cardiovascular assessment is the structured review. It asks what was found, what was done, what was not done, and what the 5-year mortality data looks like for your anatomy and EF. This is not a second opinion on the procedure already performed. It is a forward-looking assessment of whether your medical therapy, your surveillance schedule, and your lifestyle modifications are aligned with what the evidence shows reduces events in patients with your findings.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.